Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levofloxacin vs Imipenem/Cilastatin in Nosocomial Pneumonia
NCT00236834Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Dec 1997
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of levofloxacin in hospital-acquired pneumonia (HAP) (2 arms), sponsored by Johnson & Johnson. Primary endpoint: Microbiological response at posttherapy. Started Dec 1997; status: completed.
02
Drugs
levofloxacin
03
Conditions
hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on NCT00236834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00236834.